title: Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.
abstract: Patients with chronic lymphocytic leukemia (CLL) that develop resistance to Bruton tyrosine kinase (BTK) inhibitors are typically positive for mutations in BTK or phospholipase c gamma 2 (PLCγ2). We developed a high sensitivity (HS) assay utilizing wild-type blocking polymerase chain reaction achieved via bridged and locked nucleic acids. We used this high sensitivity assay in combination with Sanger sequencing and next generation sequencing (NGS) and tested cellular DNA and cell-free DNA (cfDNA) from patients with CLL treated with the BTK inhibitor, ibrutinib. We also tested ibrutinib-naïve patients with CLL. HS testing achieved 100x greater sensitivity than Sanger. HS Sanger sequencing was capable of detecting < 1 mutant allele in background of 1000 wild-type alleles (1:1000). Similar sensitivity was achieved with HS NGS. No BTK or PLCγ2 mutations were detected in any of the 44 ibrutinib-naïve CLL patients. We demonstrate that without the HS testing 56% of positive samples would have been missed for BTK and 85% of PLCγ2 would have been missed. With the use of HS, we were able to detect multiple mutant clones in the same sample in 37.5% of patients; most would have been missed without HS testing. We also demonstrate that with HS sequencing, plasma cfDNA is more reliable than cellular DNA in detecting mutations. Our studies indicate that wild-type blocking and HS sequencing is necessary for proper and early detection of BTK or PLCγ2 mutations in monitoring patients treated with BTK inhibitors. Furthermore, cfDNA from plasma is very reliable sample-type for testing.
authors.affiliation: NeoGenomics Laboratories, Irvine, CA, USA.
authors.forename: Adam
authors.initials: A
authors.lastname: Albitar
authors.affiliation: NeoGenomics Laboratories, Irvine, CA, USA.
authors.forename: Wanlong
authors.initials: W
authors.lastname: Ma
authors.affiliation: NeoGenomics Laboratories, Irvine, CA, USA.
authors.forename: Ivan
authors.initials: I
authors.lastname: DeDios
authors.affiliation: NeoGenomics Laboratories, Irvine, CA, USA.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Estella
authors.affiliation: Medical Oncology Service, National Cancer Institute, Bethesda, MD, USA.
authors.forename: Inhye
authors.initials: I
authors.lastname: Ahn
authors.affiliation: Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA.
authors.forename: Mohammed
authors.initials: M
authors.lastname: Farooqui
authors.affiliation: Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA.
authors.forename: Adrian
authors.initials: A
authors.lastname: Wiestner
authors.affiliation: NeoGenomics Laboratories, Irvine, CA, USA.
authors.forename: Maher
authors.initials: M
authors.lastname: Albitar
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004247:DNA / Q000032:analysis; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D059014:High-Throughput Nucleotide Sequencing / Q000379:methods*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics*; D051966:Phospholipase C gamma / Q000235:genetics*; D010880:Piperidines; D016133:Polymerase Chain Reaction; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012680:Sensitivity and Specificity
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D004247:DNA; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human; D051966:Phospholipase C gamma; D000225:Adenine
keywords: BTK; CLL; PLCγ2; ibrutinib; resistance